enGene Therapeutics (ENGN) Total Non-Current Liabilities (2022 - 2024)
enGene Therapeutics (ENGN) posted quarterly Total Non-Current Liabilities of $36.6 million for Q3 2024, up 19.59% quarter-over-quarter from $30.6 million in Q2 2024.
enGene Therapeutics (ENGN) Total Non-Current Liabilities (2022 - 2024) Analysis & Trends
enGene Therapeutics (ENGN) has reported Total Non-Current Liabilities for 3 consecutive years, with $36.6 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Total Non-Current Liabilities changed N/A year-over-year to $36.6 million; the TTM figure through Jul 2024 stood at $36.6 million (changed N/A YoY), while the FY2023 annual figure was $14.5 million, down 59.74% from the prior year.
- Total Non-Current Liabilities advanced to $36.6 million in Q3 2024 per ENGN's latest filing, from $30.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $36.6 million in Q3 2024 and bottomed at $14.5 million in Q4 2023.
- Historically, Total Non-Current Liabilities has averaged $29.7 million across 3 years, with a median of $31.0 million in 2024.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 59.74% in 2023 and fell as far as 59.74% in 2023.
- enGene Therapeutics' Total Non-Current Liabilities stood at $35.9 million in 2022, then tumbled by 59.74% to $14.5 million in 2023, then surged by 152.54% to $36.6 million in 2024.
- Business Quant data shows ENGN's Total Non-Current Liabilities at $36.6 million in Q3 2024, $30.6 million in Q2 2024, and $31.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 9.32 Bn |
| 10 | enGene Therapeutics | 123.41 Mn | 123.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2024 | 36.55 Mn |
| Apr 30, 2024 | 30.56 Mn |
| Jan 31, 2024 | 31.04 Mn |
| Oct 31, 2023 | 14.47 Mn |
| Oct 31, 2022 | 35.95 Mn |